Creutzfe ldt-Jakob dis ease is a rare typ e ofsp ongiform encep halop athy. AjJected patients present with cons titutional sy tnp toms, which progress to severe mental deterioration and mov em ent disorders. Dizzin ess is the most co mmo n early otologic symptom. Fe w reports in the literature desc ribe p atients with Creutzfeldt-Ja ko b dise ase who p rese nt with sudde n-onse t hearing loss as their primary sy mp tom fo r see king treatm ent. This paperdiscusses one such p atient and rev iews the clinical presentati on , treatm ent op tions, and rele vant literature.
The patient develop ed prog ressiv e imb alance and had fallen three times in the 2 weeks prior to pre sentation. Her fam ily also noted that she had seanning spee ch. Th e presumptive diagnosis after evaluation in a loealurgent eare department was Meniere' s disease. The patient's past med ical history was unr em ark abl e exeept for abdominallysis ofadhes ions and cataraet surg ery.
On physic al exa mination, the pati ent exh ibited poor eye tracking, shuffling ga it, and truneal ata xia with intention tremor. Audiometri e testing (figure I) rev ealed moderateto-severe bilateral sensor ineural hearing loss with poorer word reeognition than would be predieted by the degree of hearing loss .
The patient wa s admitted for furth er evaluation with a possible diagnosis of cerebrovascular accident. Seve ral blood tests (erythroeyte sedimentation rate, angiotensineon vertin g enzyme I levels, Lyme titer, folat e, vitamin B1 2, eeruloplasmin, CS F analysis, thyroid panel , CH EM-7, and CBC) we re ordered, all of which were negative or w ithin nonnai Iimits. Magnetic resonanee imag ing of the brain (figure 2) indieated some periv entrieular white matter change; magnetic resonanee angiography and earotid ultra sound were norma!. In the first 2 weeks afte r her adm ission, the patient began to dev elop involuntary j erk ing of the upper ext remities and increased tremo r and startle myoelonus . Her symptoms continued to progress, and she developed aphasia and aprax ia. An aud itory brainstem response test was attempted, but wa veforms were not reprodueible. Eleetroencepha lography was nonspe eific, with back ground slow ing and oeeasional triph asie wave s (figure 3), ind icat ing a g lobal encepha lopathy with lack ofperiodicit y. A right frontal brain biopsy confirmed CJO by Western blot analysis with the presenee of proteaseresistant prion protein .
Follo win g the initial workup, the patient wa s admitte d to a rehabilitation unit to begin physical th erapy .The patient's dementia and level of eonseiousness deteriorated rapidly, and sh e expired less than 2 months from her original date of adm ission.
Discussion
Creut zfeldt-Jakob dise ase is a rare disorder oftransmissibl e spong iform eneepha lopathy charaeteri zed by progre ssive 535 Coblatiorf-Assisted Tonsillectomy gets your patients back to normal fast Pediatric mean pain score' (1=less pain , Iü-more pain) 9 8 Compared to electrocautery, post-op results were impressive: 750  1500  3000  6000   I   I  I   ,   ,   ,   I  I   ,   I  I  I   I  I   ,   I   ,  ,   I   I   I   ,  ,   I  I   ,   ,   I   ,   , , , 110 deme ntia. It is a prion disease requiring a prote in component (prion) for transmissibility, similar to kuru , bovine spongifonn encephalopathy (mad cow disease), and scrapie. Creutzfeldt and Jakob, independently, first described the disease. The first published description was of a 22-yearold woman wit h a I-year history of progressive dementia, spasticity, ataxia, and start le myoc lonus.' Sim ultaneo usly, Jakob identified 3 patients wit h a unique syndro me.>' All were older than Cre utzfe ldt's patie nt and demonstrated a destructive process in the cerebra l cortex, especially in the rolandic region, caudate , putamen, and thalamus . The first name for this disease was "spastic pseudosclerosis" because ofits similarity to other diseases, such as multiple sclerosis and amyotrophic lateral sclerosis. A family with the disease was then described in the early to mid -1900s in which II members of the fam ily had died of the same process,"
Multiple for ms ofCJD have bee n recognized. The first is the typ ical form, otherwise known as subac ute spongiform encep halopat hy. Variants are described on the basis of localization of the disease process and presenting symptoms . Fami lial fatal insomnia invo lves the tha lamu s, and Heidenhain 's variant involves the occipitallobes. Relat ed prion disorders include Gerstrnann-Straussl er-Scheinker syndrome, which is marked by cerebellar ataxia; and prion prote in (Pr P) and atypical forms of CJD caused by oth er mutations of the PrP ge ne (P RNP) . 6 Th e typical form of CJD has a mean age at onset of 60 ± 9 years. This is in con trast to Alzheimer 's disease, the incidenee ofwhich increases markedly after age 60. There is no reported sex predilection for the disease. The annual incidenee is 0.5 to 2 cases per mil lion. !? Approximately 15% of cases are familial , caused by a mutation on the ge ne encoding the PrP, and are transmitted in an autosomai do minant pattern." Penetrance in fami lial cases also increases wit h age . A lthough 60% of fami lial mut ations of the PRNP invo lve codon 200, mult iple codons may be involved in members ofthe same fam ily, as we il as in var iants ofCJD. 6 Most cases are sporadic, but iatrogenic causes have been high ly pub licized . These include transmission via hum an cadaveric pituitary growth hormone," comeal tran sp lants, dural grafts, and EEG depth electrodes. ' The iatrogenic cases involving pituitary hormone occurred in patients younger than 40 years ofage , servi ng to differentiate them from sporadic cases. " One third of patients experience prodro ma l co nstitutional symptoms, such as changes in sleepi ng and eati ng patterns and asthenia. Up to one fifth of the patients have asudden onset ofneurologic syrnptorns.? Dizziness is the most common oto logic sy mptom noted. To date, only two other Engli sh-Ianguage reports of deafness as the primary and change in hearing. ' Our patient had a progressive inereas e in baseIine hearing loss with dysequilibrium but no vertigo. Patients with this constellation of symptoms may be diagnosed initi ally with a peripheral vestibulocochlear disorder, as in the cas e ofourpatient. Otherear!y symptoms are visuospatial or cerebellar in origin, such as visual field defects, diplopia, and ataxia.':?
Aud iometric testing in these patients may reveal a poor word discrimination score that is out of proportion with the pure-tone hearing defic it. The role of imaging in the diagnosis ofCJD is controversial. Computed tomography demonstrates volume loss in wh ite matter and cortical atrophy with ventricular enlargement. In later stages of the disease, subdural fluid collections may be present. MRI , espec ially using high er-strength magnetic fields , may show high signa ls on T2 imag es in areas corresponding to the pathologic process, such as the basal gangIia, cortex, and periventricular white matter. Narrow-window techniques may increase the sensitivity for detecting early stages of CJD.ll Single photon emi ssion computed tomography (SPECT) has revealed cerebral perfusion deficits in CJD that may be used to differentiate it from other dementias, such as Alzheimer 's disease. The correlation of SPECT seanning with the pathologic process behind CJD remains to be studied.'? CJD progresses relentlessly as patients develop further mental deterioration and movement disorders, such as chorea and myoelonus. Seizures may occur, and electroencephalographic testing is performed to assi st in diagnosis.? More than 90% of patients in one series had findings of myoelonus, characteristic periodic sharp wav e complexes (PSWCs), or both. 9 The accuracy ofthese PSWCs is debatable, with one series reporting a sensitivity of 67% and a somewhat higher specificity of 86%. Serial EEGs are recommended to help increase sensitivity."
The ultimate diagnosis ofCJD depends on neuropathologic findings in correlation with elinical history. A elass ie triad ofspongiform change, neuronalloss, and ast rocytosis has been weil described (figure 4) . However, spongiform change itself remains nonspecific; the onl y con sistent 10cation is in the head of the caudate nucleus. Spongiform change may also be absent in patients with a long duration of the disease.!' PrP immunoreactivity may be performed for confirmation but may not distinguish typical CJD from Speeial eare should be exereised when eevimeline is taken by geriatrie patients, considering the greater frequency of deereased hepatie, renal, or eard iae funetion Cevimeline ean potentially alter eardiovaseular fu nction. Consult the brief summary of prescribing information eoneerning these potentia l effeets Caution should be advised while driving at ni ght or performing hazardous activities in redueed lighting
Safety considerations
The most frequently reported adverse events associated with the pharmacologie action of a musearinie agonist (>10% incidenee) in elinieal trials of eevimeline were: exeessive sweating, nausea, rhinitis, and diarrhea. Consult the brief summary of prescribing infarmation for other adverse events Cevimeline is eontraindieated in patients with uneontrolled asthma, known hypersensitivity to the drug, and in aeute iritis and narrow-angle (angle-c1osure) glaueoma Consult the briefsummary of preseribing infarmation for safety considerations coneerning drug interactions, special populations, patients with a history of eardiae disease, controlled asthma, chronie bronchitis, COPD, nephrolithiasis, or eholelithiasis Please see accompanying brief summary of prescribing information. In onesubjeel with lupus erythem atosus reeeivingeone omi lantmultipl e drug therapy, a highl y eleva ted ALT level wasnoted atte r the fourthweek of eevimelinetherapy. In twoothersubjee ts reeeiving eevimelinein the eli nieal Irials, veryhighASTlevel s \'Jere noled. The signilieanee of thesefindings is unknown.
Additio naladve rseevents (relationshipunknown)w hiehoeeu rred inothere!inieals ludies (palient populat iondifferenllrom Sjõg ren'spalients) are aslollows: eho linergie syndrome, blood pressure fluetuation, eardiomegaly, posturai hypotension. aphas ia. eonvul sions, abnormal gai l, hyperesthesia, paralysis, abnormal sexual funet ion, enlarged abdomen,ehange inbowel habits,g um hyperplasia,intestinalobstrue tion, bundlebraneh bloek,inereased erealinephosphokinase, el ectrolyte abnormality, glyeosuria, gout ,h yperkal emia, hyperpr oteinemia, iner easedlaetie dehydrogenase(LOH), inereased alkalinephosphalase, fai lure10thrive. abnormal platel els, agg ressivereaetion, amnesia, apalhy,delirium, delusio n. dementia, illusion, impotenee. neurosis. paranoid reaetion, personality disorder, hyperhemoglobinemia, apnea. ateleetasis, yawning, oliguria, urinary retention, dislended vei n, lymphocytosis MANAGEMENT OF OVEROOSE: Management of the signs and symptoms of aeut e overdosage should behandled in a ma nner eonsistent withthatindieated for other musearinie agonists: generalsupportivemeasu resshould beinslituted. Il medieall y indiea ted, alropine, an anti-ehol inergieagent may be of val ueasan anti dotefor emergencyusein patients who havehadanoverdose of cevi meline.J1 medicaltyindieated,epinephr inemay alsobe ol val ueint hepreseneeol severecardiovaseular depressionorbronehoeonstrielion. lt is not known il eevimelineis dialyzable. DOSAGE AND ADMINISTRATION: Thereeommendeddose of cev imelinehydroehtorideis 30 mg takenthreelimes a day . Thereis insullieient saletyinformation to support doses grealerIhan30 mgtid. There is alsoinsufl ieienlevidenee lor addi tiona l ellieaey 01 eevimelinehydroehl oride atdoses greater than30 mgt id. Cevimel ine did not adversel y alfeet therepr oductive performance or fertility of male Sprague·Oawleyrats when administered for 63 days prior to matingandthroughout the peri odof mati ng atdosages up to 45 mglkglday (approximately 5 times the maximu m reeommended dose for a 60 kghuma n followingnormali zationol lhedata on thebasis of body surfaee area est imates). Females that were treated wilh eevimelineat dosa gesupto 45mglkg/dayfrom 14daysprior to mat ingthroughdayseven of geslation exhibi teda statistiea lly signifieantrysmaller numberof implant ations than did eontral animals. Pregnaney: PregnancyCategory C. Cevimeline was associated wi th a reduetion in themean number 01implantat ions whengivento pregnant Sprague -Oawleyrats Irom14days prior to maling throughday seven 01 geslati onat a dosage of 45 mglkg/day (approximatel y 5 times themax imum reeommended dose fora 60 kg human when eomparedon thebas is 01body surfaee areaeslimat es). This eUeet mayhave been see ondary to maternailoxieity. There arenoadequate and well·eontroll ed studi esin pregnant women.Cevimel ineshould beused during pregnancyonlyil thepolenllalbenefi t justilies thepotential riskto theletus. Nursing Molhers: It is not known whetherthis drug is seeretedin human milk.Because manydrugsareexereted in humanmil k, andbeeause 01thepot ent lal ror seriousadversereaetions in nursinginlantsfromEVOXAC@ . a deeision should bemade whelher to diseont inuenursing or discontinue the drug, taki ng into ae eount theimportanee 01the drug to themother . Pediatric Use:Safetyand eflee liveness in ped iatric pati ents havenoi been eslablished. GeriatricUse: Although el iniealstudies01 eevimelineineluded subjeets over the age of 65, thenumbers werenoi suffieient to determine whelher theyrespond di lferentrylromyounger subjeets. Speeia l eareshouldbeexereised when eevimeline trealment is initiatedinanelderly patienl, eonsi deringlhegrealer frequeneyofdeereased hepatie, renal. or eardiae lunelion.andoleoneomitant disease orotherdrug therapy in the elde rly. AOVERSEREACTIONS: Cevimeline wasadministered to 1777patlenls during eli nieal lrials worldwide, includingSjõgren's patients andpatlents with othereonditions. Jn plaeebo-eontrolled Sj õgren's studiesin theU.S., 320patienls reeeived eevimelinedoses ranglng from 15 mg tid to 60 mgtid, 01whom 93% werewomen and 7% weremen. Oemographie distribution was90% Caueasian, 5% Hispanie. 3%Black , and 2% 01other origi n. Inthese studie s, 14. 6% 01 patiems diseontinuedIreat ment with eevimel ine duet o adverseevenls.
The lollowing adverseeventsassociated withmusearinieago nismwereobserved in theelinieallrials 01eevimel inein Sjõg ren's syndromepatien ls: 
